Payment overview · 2025
General Payments
$525.59
30 reported records · 11 companies
Healthcare provider profile · identity verified
Jerome Michael Rutowski, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · AMHERST, NY · NPI 1780996769
Verified facts
What the public records show
CMS Open Payments records show Jerome Michael Rutowski, FNP received $525.59 in general payments during 2025 across 30 reported records.
Novo Nordisk Inc accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.18 | 29.1% | 15 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $119.68 | 22.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.44 | 12.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.50 | 8.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $43.45 | 8.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.37 | 3.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $17.35 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.43 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.72 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.53 | 3.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.94 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $525.59 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $119.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $108.61 | 10 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $53.14 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.57 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.57 | 5 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $43.45 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 175 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 376 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 371 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 344 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 99 |
| Lisinopril | Lisinopril | 293 | 89 |
| Omeprazole | Omeprazole | 277 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 70 |
| Losartan Potassium | Losartan Potassium | 209 | 62 |
| Furosemide | Furosemide | 205 | 55 |
| Simvastatin | Simvastatin | 200 | 64 |
| Gabapentin | Gabapentin | 187 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 49 |
| Eliquis | Apixaban | 175 | 40 |
| Alprazolam | Alprazolam | 162 | 46 |
| Metformin Hcl Er | Metformin Hcl | 157 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 34 |
| Metformin Hcl | Metformin Hcl | 138 | 43 |
| Irbesartan | Irbesartan | 127 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 27 |
| Ibuprofen | Ibuprofen | 107 | 37 |
| Jardiance | Empagliflozin | 107 | 24 |
| Valsartan | Valsartan | 106 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 21 |
| Potassium Chloride | Potassium Chloride | 96 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 26 |
| Xarelto | Rivaroxaban | 92 | 24 |
| Carvedilol | Carvedilol | 90 | 27 |
| Sertraline Hcl | Sertraline Hcl | 88 | 22 |
| Tramadol Hcl | Tramadol Hcl | 85 | 14 |
| Azelastine Hcl | Azelastine Hcl | 84 | 34 |
| Azithromycin | Azithromycin | 84 | 70 |
| Allopurinol | Allopurinol | 72 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 13 |
| Bumetanide | Bumetanide | 65 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 23 |
| Baclofen | Baclofen | 63 | 28 |
| Synthroid | Levothyroxine Sodium | 60 | 19 |
| Glipizide | Glipizide | 59 | 14 |
| Lorazepam | Lorazepam | 59 | 11 |
| Ozempic | Semaglutide | 59 | 12 |
| Atenolol | Atenolol | 56 | 18 |
| Ezetimibe | Ezetimibe | 56 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 17 |
| Montelukast Sodium | Montelukast Sodium | 56 | 17 |
| Celecoxib | Celecoxib | 55 | 15 |
| Famotidine | Famotidine | 55 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 13 |
| Prednisone | Prednisone | 52 | 21 |
| Rybelsus | Semaglutide | 50 | 12 |
| Spironolactone | Spironolactone | 50 | 20 |
| Entresto | Sacubitril/Valsartan | 44 | 11 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 12 |
| Amoxicillin | Amoxicillin | 34 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 13 |
| Nifedipine Er | Nifedipine | 32 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Constulose | Lactulose | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Soma | Carisoprodol | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Norvasc | Amlodipine Besylate | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $525.59 · 30 records | Novo Nordisk Inc | CAMZYOS, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, ENTYVIO, FREESTYLE LIBRE 3, GARDASIL 9, INJECTAFER, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, WATCHMAN, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error